Therefore, in our study, based on these predictions about new target genes for ER, it is desirable to develop investigational small molecules for DLBCL (e.g., novel monoclonals), which also provides new ideas for the treatment of clinical DLBCL patients. The gene discussed is ESR1; the disease is diffuse large B-cell lymphoma.